Who are botulinum toxin Type A (24 U)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NT 201, Intradetrusor Botox Injections, Chemodenervation (4 months), Botox infiltration, Azzalure or Dysport, Xeomin®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botulinum-toxin-type-a-24-u.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

botulinum toxin Type A (24 U) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

botulinum toxin Type A (24 U) (botulinum toxin Type A (24 U)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin. Area: Neurology.

phase 3 Neurotoxin SNARE complex Neurology Biologic Live · refreshed every 30 min

Target snapshot

botulinum toxin Type A (24 U) (botulinum toxin Type A (24 U)) — Allergan. Botulinum toxin Type A works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
botulinum toxin Type A (24 U) TARGET	botulinum toxin Type A (24 U)	Allergan	phase 3	Neurotoxin	SNARE complex
NT 201	NT 201	Merz Aesthetics GmbH	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Chemodenervation (4 months)	Chemodenervation (4 months)	University of Wisconsin, Madison	marketed	Botulinum toxin	SNARE complex (synaptobrevin, SNAP-25, syntaxin)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Azzalure or Dysport	Azzalure or Dysport	Galderma R&D	marketed	Botulinum toxin type A	SNARE complex (synaptosome-associated protein)
Xeomin®	Xeomin®	ATGC Co., Ltd.	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery at neuromuscular junction)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin class)

Allergan · 2 drugs in this class
Aránzazu Vázquez Doce · 1 drug in this class
Ulthera, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). botulinum toxin Type A (24 U) — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-type-a-24-u. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing